Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019
Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
155 citing papers in PubMed, 4 syntheses or guidelines pooled it, 317 citations in OpenAlex.
- Practice guideline for management of endometrial cancer in Thailand: a Thai Gynecologic Cancer Society consensus statement.Journal of gynecologic oncology · 2025Guideline
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer.ESMO open · 2023Guideline
- ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.Virchows Archiv : an international journal of pathology · 2021Guideline
- Efficacy and Toxicity of Adjuvant Therapies for High-Risk Endometrial Cancer in Stage I-III: A Systematic Review and Network Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2020Pooled it
- Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249.Gynecologic oncology · 2026Trial
- Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial.The Lancet. Oncology · 2025Trial
- Randomized comparison between sentinel lymph node mapping using indocyanine green plus a fluorescent camera versus lymph node dissection in clinical stage I-II endometrial cancer: a Korean Gynecologic Oncology Group trial (KGOG2029/SELYE).Journal of gynecologic oncology · 2022Trial
- [Clinical implications of the PORTEC-3 trial for the treatment of high-risk endometrial cancer].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020Trial
- Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.The Lancet. Oncology · 2019Trial
- Improved Overall Survival Associated With Vaginal Cuff Brachytherapy Boost for Stage II Endometrioid Endometrial Cancer.Advances in radiation oncology · 2026Article
- Markedly elevated alpha-fetoprotein leading to the diagnosis of high-grade endometrial carcinoma during hepatocellular carcinoma surveillance.Gynecologic oncology reports · 2026Article
- Annual hazard rates for early-stage endometrial carcinoma after postoperative radiotherapy under FIGO 2023 staging system: results from a population-based single-center cohort study.Journal of gynecologic oncology · 2026Article
- Risk-Based Survival Outcomes in Early-Stage Endometrial Cancer: Impact of Radiation Therapy.Journal of Korean medical science · 2026Article
- Postoperative radiation therapy in women with FIGO stage I clear cell and papillary serous carcinomas of the uterus: an analysis of the SEER database.Journal of gynecologic oncology · 2026Article
- Statement by the Uterus Commission of the Arbeitsgemeinschaft Gynäkologische Onkologie [German Gynecological Oncology Group] (AGO) on the ESGO-ESTRO-ESP Guideline 2025.Geburtshilfe und Frauenheilkunde · 2026Article
- Nomogram for predicting cancer-specific mortality risk in endometrial cancer after postoperative radiotherapy.Translational cancer research · 2026Article
- Integrating molecular classification and micrometastasis in sentinel lymph nodes in endometrial cancer management.Revista da Associacao Medica Brasileira (1992) · 2026Article
- Limited pelvic radiotherapy in post-operative uterine carcinoma.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026Article
- Recommendations for the treatment of endometrial cancer in settings with limited resources: report from the International Gynecological Cancer Society consensus meeting.Frontiers in oncology · 2026Article
- Predictive value of IGF2BP2 for endometrial cancer recurrence: a multicenter study.Frontiers in oncology · 2026Article
95 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
19 authors at 17 institutions in 2 countries.
Funding
Abstract
purposeThe primary objective was to determine if vaginal cuff brachytherapy and chemotherapy (VCB/C) increases recurrence-free survival (RFS) compared with pelvic radiation therapy (RT) in high-intermediate and high-risk early-stage endometrial carcinoma. PATIENTS AND
methodsA randomized phase III trial was performed in eligible patients with endometrial cancer. Eligible patients had International Federation of Gynecology and Obstetrics (2009) stage I endometrioid histology with Gynecologic Oncology Group protocol 33-based high-intermediate-risk criteria, stage II disease, or stage I to II serous or clear cell tumors. Treatment was randomly assigned between RT (45 to 50.4 Gy over 5 weeks) or VCB followed by intravenous paclitaxel 175 mg/m
resultsThe median age of the 601 patients was 63 years, and 74% had stage I disease. Histologies included endometrioid (71%), serous (15%), and clear cell (5%). With a median follow-up of 53 months, the 60-month RFS was 0.76 (95% CI, 0.70 to 0.81) for RT and 0.76 (95% CI, 0.70 to 0.81) for VCB/C (hazard ratio, 0.92; 90% confidence limit, 0.69 to 1.23). The 60-month overall survival was 0.87 (95% CI, 0.83 to 0.91) for RT and 0.85 (95% CI, 0.81 to 0.90) for VCB/C (hazard ratio, 1.04; 90% confidence limit, 0.71 to 1.52). Vaginal and distant recurrence rates were similar between arms. Pelvic or para-aortic nodal recurrences were more common with VCB/C (9%
conclusionSuperiority of VCB/C compared with pelvic RT was not demonstrated. Acute toxicity was greater with VCB/C; late toxicity was similar. Pelvic RT alone remains an effective, well-tolerated, and appropriate adjuvant treatment in high-risk early-stage endometrial carcinomas of all histologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.